Key result
Review explores how novel HF drugs impact QRS width and ventricular dyssynchrony.
Why the study?
Ventricular dyssynchrony with a wide QRS interval is a major adverse feature of HF, prompting an analysis of how newly introduced HF molecules affect QRS width and potential outcomes.
Do new pharmacological therapies improve QRS width in patients with heart failure and ventricular dyssynchrony?
Do new pharmacological therapies improve QRS width in patients with heart failure and ventricular dyssynchrony?
This review explores the potential for new pharmacological therapies to positively affect QRS width and ventricular dyssynchrony in heart failure patients.
Answers are grounded in this paper and cite their sources.
New agents' QRS effects remain exploratory; dedicated randomized trials are needed before any clinical consideration.
Heart failure (HF) is a highly prevalent cardiovascular clinical syndrome. Health care spending on HF treatment is high. Therefore, its treatment has generated a great deal of interest in pharmacological research in recent years. Recent guidelines have introduced several molecules for the treatment of HF that have demonstrated safety, and above all, efficacy. One of the worst aspects of HF is ventricular dyssynchrony (VD) with a wide QRS interval. Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits.
No takes yet. Share an insight, caveat, or question.
Mauriello et al. (2025) conducted a review in Heart failure with ventricular dyssynchrony and wide QRS. New pharmacological molecules was evaluated on QRS width. New pharmacological molecules for heart failure are reviewed to analyze their effects on QRS width and potential benefits in patients with ventricular dyssynchrony.
Synapse has enriched 10 related papers. Consider them for comparative context: